AC
MRTX

Athanor Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Athanor Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,406
Closed -$926K – 851
2021
Q1 		$926K Sell
5,406
-9,396
-63% -$1.86M 0.02% 366
2020
Q4 		$3.25M Buy
14,802
+10,230
+224% +$2.21M 0.07% 155
2020
Q3 		$759K Sell
4,572
-11,878
-72% -$1.63M 0.03% 272
2020
Q2 		$1.88M Buy
+16,450
New +$1.6M 0.1% 121
2020
Q1 		– Sell
-22,500
Closed -$2.9M – 380
2019
Q4 		$2.9M Buy
22,500
+1,840
+9% +$177K 0.13% 97
2019
Q3 		$1.61M Buy
20,660
+13,760
+199% +$1.29M 0.1% 85
2019
Q2 		$711K Buy
+6,900
New +$537K 0.09% 83

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Athanor Capital's MRTX Position: Q2 2021 in Review

Athanor Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 5,406 shares — an estimated $926K sold.

Athanor Capital first reported a position in MRTX in Q2 2019 and held it in 7 quarters. The position peaked at $3.25M in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Athanor Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 5,406 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $926K.
  • Athanor Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Athanor Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $3.25M in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.